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ABSTRACT
Proteolysis of Coronavirus spike proteins is required for virus infectivity.
Cleavage of spike at the appropriate time and location results in efficient activation of
viral entry into host cell. Type II transmembrane serine proteases (TTSPs), specifically,
transmembrane protease serine 2 (TMPRSS2) when expressed on target cells, enhance
SARS coronavirus entry by activating cleavage of spike. TMPRSS2, when expressed in
virus producing cells, is known to proteolytically activate influenza virus HA0 and
Human Metapneumovirus F0 glycoproteins. In this study, I investigated the effect of
TTSPs expressed in Coronavirus producer cells. Murine Hepatitis Virus strain A59
(MHV A59) viruses produced in the absence of TMPRSS2 were found to require the
activity of target cell proteases - either cell surface serine proteases or endosomal
acidophilic proteases - for entry. MHV A59 viruses produced in the presence of
TMPRSS2 were less infectious overall, but a portion of the viruses contained “preprimed” S proteins and were activated for entry in the absence of target cell protease
activity. These findings indicate that coronaviruses can be proteolytically activated either
in virus-producing cells or target cells and the timing of spike cleavage is crucial to virus
infectivity.
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CHAPTER ONE
INTRODUCTION
Viruses are obligate intracellular parasites that invade cells and subsequently
subvert the host cell machinery to complete their life cycle. Entry into host cells is
mediated by viral surface proteins which engage with an attachment factor or virus
receptor on the target cell surface. In the case of enveloped viruses, entry is mediated by
surface glycoproteins [1]. Following receptor binding, enveloped viruses enter the host
cell by membrane fusion, which occurs either at the plasma membrane or after
endocytosis at endosomal membranes [2-4].
Coronaviruses are enveloped, positive-sense, single-stranded RNA viruses that
have a broad range of tropism, infecting mammals and birds, causing respiratory,
gastrointestinal, hepatic, kidney and brain infections. Mouse hepatitis viruses (MHVs)
such as MHV strains A59 and 2, have been studied extensively as models for coronavirus
biology and are known to cause hepatitis, diarrhea, respiratory infections and
demyelinating infections of the central nervous system[5, 6] . Human coronaviruses (HCoVs), namely HCoV-NL-63, HCoV-229E and HCoV-OC43, cause primarily mild
respiratory tract infections, while human SARS-CoV is notable as the most pathogenic,
causing Severe Acute Respiratory Syndrome (SARS) [7].
Spike (S) proteins mediate CoV entry into host cells via receptor binding and
membrane fusion. S glycoproteins are trimeric projections on the virus envelope and are
1
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the sole viral mediators of attachment and entry, and hence are central determinants of
virulence and host tropism[8]. S proteins are synthesized at the endoplasmic reticulum
and undergo oligomerization and carbohydrate processing during maturation through the
cellular secretory pathway to emerge as a heavily N-glycosylated type I membrane
proteins, assembled as trimers on the virion envelope[9]. S proteins belong to the class I
fusion proteins, which are synthesized as precursors requiring proteolytic cleavage by
host proteases to be activated for cell entry [1, 10, 11]. For some CoVs, such as MHV
A59, S cleavage can occur during maturation in virus producer cells [12], while other
CoVs, such as SARS-CoV and MHV2, are produced with uncleaved spikes[9, 13-15] that
have to be subsequently cleaved during entry into target cells after receptor binding [16,
17].
Proteolytic cleavage positions the S proteins in an energy-rich metastable
configuration, and renders them capable, upon further refolding events, of driving the
energetically unfavorable task of drawing viral and target cell membranes in close
apposition.
Figure 1 provides linear depictions of SARS CoV, MHV2 and MHV strain A59
spike proteins and highlights domains involved in cell receptor binding (RBDs) and
virus-cell membrane fusion The currently known sites of proteolytic cleavage are also
shown.
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Figure.1 Schematic depiction of Spike proteins of SARS CoV, MHV A59 and
MHV2:SARS CoV and MHV 2 spike proteins are synthesized as uncleaved
glycoproteins which require target cell proteases for activation, while MHV A59 spike is
cleaved during assembly. SARS CoV S undergoes a second activating cleavage at S2
(R797), immediately N-terminal to its fusion peptide [61,62]. The S1 subunit contains a
signal peptide (SP), the receptor binding domain (RBD) while the transmembrane S2
subunit contains the fusion peptide (FP), heptad repeat (HR) sequences HR1 and HR2
which mediate membrane fusion, a transmembrane domain (TM) and a short cytoplasmic
tail (CT).
The N-terminal subunit S1 contains a receptor binding domain (RBD).The Cterminal S2 subunit contains a hydrophobic fusion peptide (FP), two heptad repeat
sequences (HR1 and HR2), a transmembrane domain(TM) and a cytoplasmic tail (CT).
The S1 subunit mediates receptor attachment via interactions between its RBD domain
and a cellular receptor, and the S2 subunit is responsible for membrane fusion. In the
case of MHV, the cellular receptor is carcinoembryonic antigen-related cell adhesion
molecule (CEACAM) [18-20] and for SARS-CoV, the receptor is angiotensin-converting
enzyme 2 (ACE2)[21, 22]. For both viruses, binding to the receptor triggers S protein
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conformational changes that render the S2 subunit fusogenic [23-26].Figure 2 is a model
depicting MHV spike-mediated membrane fusion; binding of spike to its receptor
CEACAM results in the dissociation of S1 from S2 and exposure of the fusion peptide,
which is inserted into the target membrane. After the fusion peptide is anchored into the
target cell membrane, the S2 subunit folds back on itself resulting in the formation of a
six-helix bundle (6HB).This 6HB consists of a central coiled-coil formed by three HR1
fragments surrounded by three anti-parallel HR2 helices. The formation of the 6HB
brings the cell membrane-anchored fusion peptide close to the S2 transmembrane
domain, thus bringing cellular and viral membrane close to each other for membrane
fusion [12, 27-30].
Viral Membrane

S2

HR2
6-HB

S1
S1
HR1
CEACAM
FP

Cellular Membrane

Figure 2. Model for coronavirus spike protein-mediated membrane fusion: ( From
“Role of Spike Protein Endodomains in Regulating Coronavirus Entry” Shulla, A., et al.,
JBC, 2009[31]) S1 subunit of spike binds to cellular CEACAM receptor and dissociates
from S2. After the fusion peptide (FP) is inserted into the target cell membrane, S2 folds
on itself, allowing Heptad Repeat 2 (HR2) to bind with Heptad Repeat 1(HR1) to form a
six-helix bundle (6-HB).The formation of the 6-HB brings the viral and cellular
membranes in contact, facilitating membrane fusion.
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There are a number of host cell proteases that cleave CoV S proteins. Furin-like
proteases cleave the MHV A59 spike late in its assembly stage [32], while trypsin and
endosomal proteases Cathepsin B and Cathepsin L are necessary for MHV2 S- mediated
cell entry[33]. The host cell proteases that have been implicated in mediating SARS CoV
entry include Cathepsin L, trypsin, elastase, plasmin, thermolysin and factor Xa[17, 34,
35]. Recent studies have also identified proteases belonging to the family of type II
transmembrane serine proteases (TTSPs) as SARS CoV entry co-factors [36-38]. In all
cases, the proteolytic events are thought to relieve structural constraints such that S
proteins can undergo the dramatic conformational transitions needed to catalyze
membrane fusions.
TTSPs are a family of membrane anchored proteases with a broad range of tissue
distribution and function. Though relatively recently identified, the TTSP family
members have been observed to play diverse roles in maintaining cellular homeostasis in
the gastrointestinal, cardiovascular and respiratory systems[39, 40].TTSPs that are
expressed in the respiratory tract, such as TMPRSS11D (also known as HAT: human
airway trypsin-like protease), TMPRSS4, TMPRSS11A, and TMPRSS2, have been
shown to activate and support multicycle replication of human influenza viruses [36, 4143]. TMPRSS2 can also activate and support replication of human metapneumoviruses
(HMPV), which, like influenza viruses, are etiological agents of infectious respiratory
tract diseases[44]. The enhancement of both influenza virus and HMPV infections by
TMPRSS2 is due to the proteolytic activation of newly synthesized, uncleaved
hemagglutinin (HA0) and F0 proteins, the surface glycoproteins of influenza and HMPV
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viruses respectively[41, 44]. In light of the activating effects that TMPRSS2 exhibits
during SARS CoV, this study set out to investigate the effects that TMPRSS2 might have
during CoV production.

CHAPTER TWO
METHODS
Cells: 293T [45], 293-ACE2 (293T cells stably expressing SARS corona virus
receptor angiotensin converting enzyme 2, ACE2) and HeLa-CEACAM (HeLa cells
stably expressing carcinoembryonic antigen cell adhesion molecule, CEACAM [46]
)were cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% fetal
calf serum (FCS), 2 mM L-Glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin
and 0.01M sodium HEPES (pH7.4). Serum Free Media(SFM) used for plaque assay
titration contained 2 mM L-Glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin
and 0.01M sodium HEPES (pH7.4). Murine 17cl1 fibroblasts [47] were grown in DMEM
supplemented with 5% tryptose phosphate broth, 5% fetal calf serum and 0.01M sodium
HEPES (pH7.4).
Coronaviruses: Murine coronaviruses MHV2 and recombinant MHV A59
viruses used in this study were propagated in 17 cl1 cells. Assays for virus cell entry were
done using recombinant MHV A59 virus, rA59EFLM, which has a firefly luciferase (FL)
reporter gene insertion between the E and M open reading frames [48].
Plasmid DNAs: Plasmids used in this study include : pNL4.3-Luc R-E (obtained
from the NIH AIDS Research and Reference Program), encoding the HIV-1 strain NL4
genome with firefly luciferase gene inserted into the pNL4-3 nef gene and expressing
luciferase as marker of gene expression[49]; pcDNA 3.1 SARS S ,encoding SARS Spike,
7
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obtained from Michael Farzan, Harvard Medical School, Boston, MA; pHEFVSV G encoding VSV glycoprotein G, from Lijun Rong, University of Illinois Chicago,
Chicago; pcDNA 3.1 CEACAM, encoding CEACAM, the receptor for murine
coronaviruses; Empty vector pCAGGS MCS[50]; pCAGGS-TMPRSS2-FLAG,
pCAGGSTMPRSS11A-FLAG, pCAGGSTMPRSS11D-FLAG, encoding FLAG-tagged
TMPRSS2, TMPRSS11A and TMPRSS11D, respectively[38]; pCAGGS A59 S
,pCAGGS A59 E, pCAGGS A59 M, pCAGGS A59 N, encoding MHV A59 S, E , M and
N proteins, respectively.
Pseudo – coronavirus production: 293T cells, seeded onto 6-well plates at
~50% confluency, were transiently transfected by the calcium phosphate precipitation
method [51, 52], with pCAGGS MCS empty vector, or with
0.001µg/0.003µg/0.01µg/0.03µg/0.1µg/0.3µg/1µg of pCAGGS-TMPRSS2-FLAG and
1µg each of pNL4-3LUC-R-E, and pHEF-VSVG/ pcDNA3.1-S-SARS. 48 hours posttransfection (h.p.t), supernatants containing secreted pseudoviruses were collected and
clarified by centrifugation at 1000xg for 10min at 4 οC. For Western blot analysis, the
pseudoviruses were purified by ultracentrifugation over a 30% sucrose cushion at
55000rpm for 1hour and 15min at 4 οC using a Beckman SW60 rotor. The pelleted
pseudovirus particles were resuspended in SDS-DTT solubilizer (0.125 M Tris [pH 6.8],
10% dithiothreitol [DTT] , 2% sodium dodecyl sulfate [SDS], 10% sucrose, 0.004%
bromophenol blue) and heated at 95 οC for 5min.
Pseudo – coronavirus transduction: For pseudovirus transduction assays, 96well plates were seeded with 293 ACE2 cells at a density of 4 x104 cells /well, infected
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with the pseudoviruses, and spinoculated at 3000rpm for 90 min at 25οC. Fresh media
was added back to the wells and the plates were incubated at 37 οC. After 48hours
transduction, the target cells were lysed with Promega reporter lysis buffer (Cat# E397A)
and luminescence measured upon addition of Promega Luciferase substrate (Cat#E1501)
with a Veritas microplate luminometer.
Production of MHV Virus-Like-Particles (VLPs): 293T cells seeded onto 6well plates were transiently transfected with 1µg each pCAGGS A59 S, E, M, N and
MCS empty vector, with or without additional 0.1/1µg of pCAGGS-TMPRSS2-FLAG.
The calcium phosphate precipitation method was used for transfection [51, 52].48 h.p.t.,
supernatants containing secreted VLPs were collected and clarified by centrifugation at
1000xg for 10min at 4C. The VLPs were purified by ultracentrifugation through a 30%
sucrose cushion at 55000 rpm for 1 hour and 15min at 4 οC with a Beckman SW60 rotor.
The pelleted VLPs were resuspended in SDS-DTT solubilizer and heated at 95 οC for 5
min for subsequent evaluation by Western Blotting.
Production of rA59EFLM from cells transiently expressing TMPRSS2:
293T cells seeded onto 10cm-diameter dishes at >60% confluency were transfected with
1µg each of pcDNA mCEACAM and pCAGGS MCS empty vector, with or without
0.01/0.1/1µg pCAGGS TMPRSS2-FLAG. The Polyethylenimine (PEI) transfection
method was used [53]. 24 h.p.t, the cells were infected with rA59EFLM at an M.O.I of
0.01. Viruses secreted in the supernatant were collected (5ml/dish) ~20 hours postinfection (h.p.i.), clarified for 10min at 2000xg, and used for infectivity assays. Viruses in
1ml of each clarified media were ultracentrifuged through 30% sucrose at 55000rpm for
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1hour and 15min at 4 οC using a Beckman SW60 rotor. The pelleted viruses were
resuspended in SDS-DTT solubilizer and heated at 95 οC for 5min for subsequent
evaluation by Western Blotting.
MHV2 production in cells transiently expressing TMPRSS2: 293T cells
seeded onto 6-well (10 cm2 per well) plates at ~50% confluency were transiently
transfected with 1µg pcDNA3.1CEACAM and pCAGGS MCS empty vector, or ,
0.01µg/0.1µg/1µg of pCAGGS-TMPRSS2-FLAG, by the calcium phosphate
precipitation method. 24 h.p.t, the cells were infected with MHV2 virus (3x108 pfu/ml) at
a multiplicity of infection (MOI) of 1.Viruses secreted in the supernatant (1.5ml/well)
were collected 20hrs post-infection, and clarified by centrifugation at 1000xg for10min at
4 οC, 100µl volumes of each clarified supernatant were used for plaque assay titration
and1ml volumes were ultracentrifuged over 30% sucrose cushions at 55000 rpm for 1
hour and 15 min at 4 οC using a Beckman SW60 rotor. The pelleted viruses were
resuspended in SDS-DTT solubilizer and heated at 95 οC for 5min for subsequent
evaluation by Western Blotting.
MHV A59 infectivity assay in the presence of drugs: HeLa-CEACAM cells
seeded onto 96 well plates at ~80% confluency were incubated with either complete
DMEM media as control or 20nM Bafilomycin A1 (Sigma Aldrich Cat #B1793) in
complete DMEM media for 30 minutes at 37οC. The cells were then treated with either
50µM Aprotinin (Sigma Aldrich Cat # A6279), or DMEM and infected with rA59EFLM
viruses that had been produced in cells expressing graded amounts of TMPRSS2, and the
infection was allowed to continue in the presence of the inhibitors. After 6 hours of
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incubation at 37οC, the infected target cells were lysed to measure luciferase
accumulations.
Plaque assay titration of MHV2 virus produced in cells transiently
expressing TMPRSS2:17Cl1 cells seeded on 6-well plates were infected with 100µl
volumes of MHV2 that had been serially diluted in serum free media. After 1 hour of
infection at 37 οC, the infection medium was aspirated and the cells were overlaid with
2ml/well of 1% Noble agar mixed with 2xDMEM containing 2% FCS and incubated at
37οC. After 48 hours, the cells were fixed in 25% Formalin, stained with Crystal violet,
and plaques were counted.
Western blot analysis: Purified HIV pseudoviruses (HIV SARS S, HIV A59 S
and HIV VSV G), MHVs (MHV2 and rA59EFLM) and MHV VLPs ,resuspended in
SDS-DTT solubilizer were heated at 95οC for 5min and subjected to SDS-polyacrylamide
gel electrophoreses (SDS-PAGE). The gels were transferred on to polyvinylidene
difluoride (PVDF) membranes which were then blocked for 1 hour with 5% non-fat milk
powder in TBST (25 mM Tris-HCl {pH 7.5}, 140 mM NaCl, 2.7 mM KCl, 0.05%
Tween 20).HIV p24 proteins were detected with mouse monoclonal anti-p24 antibody (
NIH AIDS Research and Reference Program) diluted 1:5000 in TBST. SARS Spike was
detected with anti-C9 tag (1D4) antibody (1:5000 in TBST). MHV2 and MHV A59 spike
proteins were detected using anti S2 (10G) mouse monoclonal antibody [15, 54] (1:2000
in TBST). MHV A59 M proteins were detected using mouse monoclonal anti-M
J.3.1[55] antibody(1:500 in TBST).

CHAPTER THREE
THE EFFECT OF TYPE II TRANSMEMBRANE PROTEASES ON PSEUDOVIRUS
AND VLP PRODUCTION
The effects of TTSPs on pseudovirus transduction:
Of the 17 known human TTSPs[39], TMPRSS11A and TMPRSS11D (Human
Airway Trypsin-like protease) and TMPRSS2 were tested for their effects on HIV-SARS
assembly because these three are expressed in the respiratory tract and have been shown
to proteolytically activate Influenza Hemagglutinin, Human Metapneumovirus F proteins
and SARS-CoV Spike-mediated entry[36, 37, 41, 44] . HIV-pseudotyped vectors
expressing the luciferase reporter gene[56] and bearing SARS-CoV S proteins were
produced in 293T cells that had been transiently transfected to express varying amounts
of TMPRSS proteins. The pseudoviruses thus produced were used to transduce 293T
cells that stably express ACE2. 2 days post-transduction, the target cells were lysed and
luciferase accumulations were measured as readout for pseudovirus entry. Figure 3A
presents a schematic diagram of this approach.
The presence of TMPRSS 11A, TMPRSS11D and TMPRSS2 in the pseudovirus
producing cells had an inactivating effect on the transducing abilities of HIV SARS
pseudoviruses, with the effect of TMPRSS2 being most potent(Fig. 3B), hence, further
study of TTSPs was pursued with TMPRSS2.
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When co-expressed in HIV-SARS and HIV-VSVG producing cells, increasing
amounts of TMPRSS2 specifically inhibited HIV-SARS S- mediated transduction , while
the transducing ability of HIV-VSVG was relatively unaffected (Fig. 4). The inhibition of
transduction observed with HIV-SARS S also extended to another CoV pseudotype, HIV
– MHV A59 (Fig. 5).
293T cells transfected with
plasmids encoding HIV-Luciferase, SARS spike
and empty vector or 0.01/0.1µg/1µg TMPRSS2,
11A and 11D

48hrs incubation at 37º C

HIV SARS S particles

293T ACE2 cells

48hrs transduction at 37º C
Target cells lysed and luciferase accumulations measured

Figure 3A. Schematic diagram depicting pseudovirus production and transduction:
293T producer cells were co-transfected with 1 µg each of plasmids encoding HIVLuciferase, SARS S and empty vector or 0.01µg/0.1ug/1ug TMPRSS2, TMPRSS11A
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and TMPRSS11D. Pseudoviruses collected 48 h.p.t were used to transduce 293-ACE2
cells.
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Figure 3B. Effect of TTSPs 2, 11A and 11D on HIV-SARS S transduction: Luciferase
values measured 2 days post-transduction were plotted on a Log10 scale. The error bars
represent standard deviations.
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Figure 4. TMPRSS2 dose-response: Transduction abilities of HIV-SARS S and
HIV- VSV G pseudoviruses produced in cells expressing graded amounts of
TMPRSS2: HIV-SARS S and HIV-VSV G pseudoviruses were produced by cotransfecting 293T cells with HIV vector, HIV-SARS S or HIV-VSV G vector and
pCAGGS Empty Vector or the indicated amounts of pCAGGS TMPRSS2-FLAG. 48
h.p.t, media containing the pseudoviruses were collected and used to transduce target
293T-ACE2 cells. Target cells were lysed 2 days post-transduction and luciferase
accumulations were measured. The error bars represent one standard deviation above and
below the mean.
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Figure 5. Transduction ability of HIV-MHV A59 S pseudoviruses produced in cells
expressing TMPRSS2: HIV-A59 S pseudoviruses were produced by co-transfecting
293T cells with HIV vector, MHV A59 S vector and pCAGGS Empty Vector or the
indicated amounts of pCAGGS TMPRSS2-FLAG. The pseudoviruses were used to
transduce target HeLa-CEACAM cells which were lysed 2 days post-transduction and
measured for luciferase accumulations. The error bars represent one standard deviation
above and below the mean.
The effect of TMPRSS2 on HIV SARS S and HIV A59 S protein cleavage:
The dramatic reduction in transduction potential mediated by TMPRSS2 (Figs. 4
and 5) suggested that TMPRSS2 might degrade CoV S proteins during pseudovirus
assembly and / or secretion.
To test this hypothesis, the HIV-SARS S and HIV-MHV A59 S pseudoparticles that were
evaluated for transduction potential (Figs.4 and 5) were purified by ultracentrifugation
and evaluated for S protein cleavage by Western immunoblotting.
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The data (Fig. 6) revealed that both SARS and MHV A59 S proteins were
degraded with increasing doses of TMPRSS2, with the degree of degradation
corresponding to the decreases in transducing abilities.

HIV A59 S

HIV SARS S
TMPR2(µg) 0

0.001 0.003 0.01 0.03

TMPR2(ug)
0.1

0.3

0

0.01

0.1

1

1
Uncleaved S
170kDa

170kDa
100kDa

S2

55kDa
55kDa
HIV Gag
HIV Gag
35kDa
25kDa

25kDa

Figure 6. S cleavage on HIV-SARS S and HIV-A59 S pseudoviruses: HIV SARS S
and HIV A59 S pseudoviruses produced in 293T cells transfected with the indicated
amounts of pCAGGS TMPRSS2-FLAG were purified by ultracentrifugation.
Resuspended pseudoviruses were evaluated by western immunoblotting for HIV p24
(anti-p24 antibody) and SARS S (anti-C9 antibody) or MHV A59 Spike (10G anti-S2
antibody)
The effect of TMPRSS2 on MHV VLP production:
HIV pseudoviruses bud at the plasma membrane, where TMPRSS2 is expressed
[57, 58], whereas authentic coronaviruses bud intracellularly at the ER-GolgiIntermediate-Compartment (ERGIC) [9, 59]. The degradation of HIV–CoV spikes
observed in Fig. 6 could have occurred during pseudovirus budding from the cell surface,
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where the spikes may be readily accessible to TMPRSS2.To determine if the site of spike
assembly plays a role in determining its susceptibility to the protease, I utilized MHV
A59 virus-like-particles (VLPs), and compared the effect of TMPRSS2 on spikes that
were either assembled on the plasma membrane or intracellularly at the ERGIC. MHV S
proteins, when expressed alone, are transported to the plasma membrane, while the coexpression of MHV structural proteins S, E, M and N can result in the self-assembly of
VLPs at the ERGIC [60, 61]. MHV VLP assembly mimics authentic virus assembly and
the secreted particles resemble authentic viruses, but the VLPs are not infectious because
they do not express viral genetic materials. This property makes the VLPs a good system
to more accurately assess coronavirus assembly in cells expressing TMPRSS2.
Briefly, 293T cells were co-transfected with plasmids encoding TMPRSS2 and
either MHV A59 S alone, or S in combination with E, M and N. Cell lysates (expressing
S alone) and secreted VLPs were evaluated for spike cleavage by immunoblotting.
The data (Fig. 7) revealed that spike proteins on MHV VLPs were degraded by
TMPRSS2, similar to the S degradation expressed alone in cells. The susceptibility of
MHV VLP spikes to TMPRSS2-mediated cleavage suggests that spikes are degraded
during their assembly in the exocytic pathway. Indeed, both TMPRSS2 and the S
proteins are thought to co-exist in the ER, Golgi and secretory vesicles comprising the
exocytic pathway. Possibly S cleavages take place internally in one or more of these
subcellular compartments.
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Figure 7. S cleavage on MHV A59 VLPs: MHV A59 VLPs were produced by cotransfecting 293T cells with MHV A59 S, E, M, N vectors and pCAGSS Empty Vector
or the indicated amounts of pCAGGS TMPRSS2-FLAG. VLPs produced were purified
by ultracentrifugation and evaluated by Western Immunoblotting for MHV A59 S and M
proteins with 10G (anti-S2) and anti-M J3.1 antibodies.

CHAPTER FOUR
TMPRSS2 AND AUTHENTIC CORONAVIRUS ASSEMBLY
Infectivity of MHV A59 viruses produced in TMPRSS2-expressing cells:
Data in the previous chapter revealed that HIV-CoV pseudoviruses secreted from
cells expressing TMPRSS2 have greatly diminished transduction potential. The effect of
TMPRSS2 on the production of authentic coronaviruses (murine coronaviruses
rA59EFLM and MHV 2) was investigated next. Here we used rA59EFLM, which
encodes the firefly luciferase gene within its genome, making assay of the luciferase
accumulated in infected target cells a good measure of viral entry and infectivity.
Fig.8A illustrates the overall experimental approach. Briefly, 293T cells that were
co-transfected to express CEACAM (the MHV receptor) and TMPRSS2 were
subsequently infected with rA59EFLM viruses. Progeny viruses secreted in the media
were collected ~20 h.p.i and used to infect HeLa-CEACAM target cells. Luciferase
accumulations were measured in the target cells at 6 hours post-infection to assess virus
entry.
Although the effect of TMPRSS2 on authentic MHV infectivities (Fig.8B) was
not as dramatic as its effect on HIV A59 pseudovirus transduction, there was about a 2log reduction in virus infectivity. The data indicated that viruses exiting cells overexpressing TMPRSS2 have reduced infectivities.

20

21
rA59EFLM virus

293T cells transfected with
plasmids encoding murine
CEACAM receptor and TMPRSS2
20hrs infection at 37º C

rA59EFLM progeny virions

HeLa-CEACAM
target cells

6hrs infection
Target cells lysed and luciferase
accumulations measured

Fig 8A.Schematic diagram of production and infectivity assay of rA59EFLM viruses
in the presence of TMPRSS2: 293T cells were co-transfected with plasmids encoding
murine CEACAM receptor and empty vector or 0.01µg/0.1 µg/1 µg TMPRSS2. 24 h.p.t,
the cells were infected with rA59EFLM at an M.O.I of 0.01. Viruses secreted in the
supernatant were collected 20 h.p.i. and used to infect target HeLa-CEACAM cells.
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Figure 8B.Infectivity of rA59EFLM viruses produced in cells expressing TMPRSS2:
Luciferase values measured 6 h.p.i in HeLa-CEACAM target cells were plotted on a
Log10 scale. The error bars represent one standard deviation above and below the mean.
MHV S cleavage by TMPRSS2:
The reduced infectivity of rA59EFLM produced from TMPRSS2-expressing cells
(Fig. 8B) suggested that S proteins were degraded during virus maturation. To determine
if that was the case, rA59EFLM viruses were purified by ultracentrifugation and
evaluated for S cleavage by Western immunoblotting (Fig. 9). Spike was detected by 10G
antibody which recognizes the HR2 region of S2, as depicted in Figure 9A.
The data in Figure 9B revealed that increasing amounts of TMPRSS2 in producer
cells degraded S proteins, in correlation with decreased infectivities observed (Fig.8B).
The viruses contained spikes that had been cleaved into ~80kDa, 72kDa, 70kDa and
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50kDa C-terminal fragments. An arginine at the P1 position is required for TMPRSS2
cleavage [39] and there are six arginine residues in the ~ 250 amino acid region between
S1/S2 and FP in the MHV S proteins. The 80kDa, 72kDa and 70kDa fragments observed
in Fig 9B correspond to TMPRSS2-mediated cleavages at sites (colored arrows in Fig
9A) lying between the well-known S1/S2 cleavage site (white arrow in Fig. 9A) and the
FP (black bar in Fig. 9A) and the 50kDa fragment corresponds to cleavage at a site Cterminal to the FP .
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Figure 9. MHV A59 S cleavage by TMPRSS2: (A) Schematic structure of spike: S
protein has a signal peptide (SP), receptor binding domain (RBD, a fusion peptide (FP),
two heptad repeats (HR1and HR2), a transmembrane domain TM and a cytoplasmic tail
(CT). The S1/S2 cleavage site is depicted by the white arrow and the black arrow depicts
the epitopes recognized by the 10G(anti-S2) antibody. The arginine residues between the
S1/S2 cleavage site and the FP are indicated. The possible TMPRSS2 cleavage sites
resulting in the p80, p72, p70 and p50 fragments are indicated with colored arrows.(B)
rA59EFLM viruses produced from 293T cells that were co-transfected with 1µg of
pcDNA mCEACAM and the indicated amounts of pCAGGS TMPRSS2-FLAG or
pCAGGS Empty Vector were purified by ultracentrifugation. Resuspended viruses were
evaluated by western immunoblotting for S (10G antibody) and M (anti-M antibody).
MHV A59 activation by TMPRSS2 in virus –producing cells:
Recent reports [62-64] have indicated that the CoV S1/S2 cleavage may be
insufficient for fusion activation, and that the S1/S2 cut is followed by a second cleavage
at a site next to the fusion peptide, termed the S2 cleavage site. This S2’ cleavage is
thought to be the most biologically relevant scission, because it lies immediately Nterminal to the fusion peptide and thus would put the fusion peptide at the extremity of
the transmembrane cleavage product. Thus the S2

cleavage would make the CoV S

proteins much like the traditional class I membrane fusion proteins that have their FPs at
termini. The 70kDa (Fig.9B) cleavage fragments observed on rA59EFLM spikes from
TMPRSS2-expressing cells could correspond to such fragments cleaved at the vicinity of
the fusion peptide, suggesting that a portion of the viruses expelled from TMPRSS2expressing cells may have “pre-activated” spikes ready to be inserted into target cell
membranes . Entry into cells by such viruses may be insensitive to inhibitors of
endosomal or cell surface proteases. To test this hypothesis, rA59EFLM viruses produced
from TMPRSS2-expressing 293T cells were used to infect target cells in the presence of
aprotinin (a membrane impermeable serine protease inhibitor [37, 65]), and/or
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bafilomycin A1 (an ATPase inhibitor which prevents the endosomal acidification
required for activity of some endosomal proteases [4, 66, 67]). Entry achieved by these
viruses was compared to the entry of viruses produced from cells (293T and 17Cl1) that
were not transfected with TMPRSS2 plasmids.
The results (Figs. 10A and B) revealed that MHV A59 viruses produced in cells
expressing TMPRSS2 were relatively resistant to aprotinin and bafilomycin. In the
presence of aprotinin, control viruses, produced from cells lacking exogenous TMPRSS2,
were inhibited by ~160-fold ( Fig. 10A) to 1000-fold (Fig. 10B) while the viruses
produced from cells overexpressing TMPRSS2 cells showed only 2-fold inhibition. This
indicated that MHV A59 viruses secreted from cells in the absence of TMPRSS2 are not
fully activated for entry and require target cell proteases (endosomal proteases or cell
surface serine proteases) for further activation, whereas TMPRSS2,in virus producer cells
could provide the activating proteolysis required for entry.
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Figure 10A.Effect of Bafilomycin and Aprotinin on the entry of rA59EFLM
virusesthat were produced in the presence of graded amounts of TMPRSS2:
rA59EFLM viruses that had been produced in 293T cells in the presence of the indicated
amounts of pCAGGS TMPRSS2-FLAG were used to infect target HeLa-CEACAM cells
in the presence of complete DMEM media (No drugs) or 20nM Bafilomycin A1 and/or
50µM Aprotinin. Cells were lysed 6 h.p.i and luciferase accumulations were measured.
Error bars represent one standard deviation above and below the mean.
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Figure 10B. Effect of Bafilomycin and Aprotinin on rA59EFLM entry:
rA59EFLM viruses that were produced in 17Cl1 cells in the absence of TMPRSS2 were
used to infect HeLa-CEACAM cells in complete DMEM media (No Treatment) or 20nM
Bafilomycin A1 and/or 50µM Aprotinin. Cells were lysed 6 h.p.i and assayed for
luciferase accumulations. Error bars represent one standard deviation above and below
the mean.
Thermal inactivation of MHV A59 viruses produced in TMPRSS2-expressing cells:
Stability of S1-S2 interactions have been correlated to thermal stability of some
strains of MHV, specifically, the neurovirulent MHV JHM.San Diego (JMH.SD)[68].
JHM.SD spikes are cleaved at the S1-S2 junction. The non-covalent interaction between
the two subunits is dissolved by elevated pH at the cell surface, and S1 dissociates
spontaneously from S2 [69, 70] , rendering the virus in a fusion-competent state. The
dissociation of S1 from S2 correlates with enhanced neurovirulence, and also tissue
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culture instability [8]. Evidence of rA59EFLM spike cleavage by TMPRSS2 at positions
near the fusion peptide (Fig. 9B, note ~ 70 kDa bands) suggested that these extra
cleavages might render the viruses thermally labile, similar to the JHM.SD viruses. To
test this hypothesis, rA59EFLM viruses were incubated at 37οC for 5,10,20,40, 80min,
and then used to infect target HeLa-CEACAM cells. At 6 hpi, target cells were lysed to
measure luciferase accumulations.
The data (Fig. 11) indicated that the MHV A59 viruses expelled from cells
expressing TMPRSS2 were indeed hyperlabile. Perhaps the preactivated viruses with
cleaved spikes undergo more rapid intrinsic denaturation over time, resulting in rapidly
declining infectivities.
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Figure 11. Thermal inactivation of rA59EFLM viruses produced in the presence of
TMPRSS2: rA59EFLM viruses that were produced in the presence of the indicated
amounts of pCAGGS TMPRSS2-FLAG were incubated at 37οC for 0, 5,10,20,40 and 80
minutes. The viruses were then used to infect HeLa-CEACAM cells. Cells were lysed 6
h.p.i to assay for luciferase accumulations.
Infectivity and Spike-cleavage of MHV2 viruses produced in TMPRSS2-expressing
cells:
MHV2 spikes, like SARS-CoV spikes, are produced uncleaved during assembly
and secretion from infected cells. Production of MHV2 viruses in TMPRSS2-expressing
cells could give insight to the infectivity of SARS-CoVs produced under similar
conditions.
To test the effect of TMPRSS2 on MHV2 production, MHV2 viruses were used
to infect 293T cells that were transfected to express murine CEACAM receptor and
TMPRSS2. Progeny viruses secreted in the media were collected 20 hpi and titered on
17Cl1 cells to assay infectivity. Purified viruses were evaluated for S cleavage by
Western Immunoblotting using anti-S2 (10G) antibody, which recognizes epitopes in the
HR2 region of the C-terminal S2 subunit (illustrated in Fig. 12C).
The results (Fig. 12) revealed that MHV2 viruses produced in the presence of
TMPRSS2 were about 20-fold less infectious than control viruses that were produced in
the absence of the protease. The presence of TMPRSS2 in producer cells seemed to result
in an inactivating cleavage of MHV2 spike at a site C-terminal to the fusion peptide (red
arrow in Figure 12C), to a ~55kDa product corresponding to the protease-resistant core of
the six-helix bundle conformation (6HB) formed during membrane fusion events.
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Figure 12. Effect of TMPRSS2 on the infectivity and Spike cleavage of MHV2
viruses: MHV2 viruses were produced in 293T cells that were co-transfected with 1µg of
pcDNA mCEACAM and the indicated amounts of pCAGGS TMPRSS2-FLAG or
pCAGGS Empty Vector. A) Viruses secreted in the media were clarified by
centrifugation and titered on 17Cl1 cells by plaque assay.B) Viruses were pelleted by
ultracentrifugation, resuspended, and evaluated by western immunoblotting for MHV2
Spike protein (10G anti-S2 antibody). C) Schematic depiction of MHV2 spike [15] with
the 10G antibody recognition site (black arrow) and the putative TMPRSS2 cleavage site
(R939, red arrow)) C-terminal to the fusion peptide (FP).

CHAPTER FIVE
CONCLUSION
Coronavirus spike is an important determinant of viral tropism. The
spatiotemporal sequence of spike cleavage is extremely important to viral pathogenicity
and the proteolytic processing that spike undergoes can differ between different
coronaviruses. SARS coronavirus spike is synthesized uncleaved and during entry; after
receptor attachment the spike undergoes sequential cleavage at the S1-S2 junction
(Fig.13, “1”), followed by cleavage at the S2

region (Fig 12.” 2”) [62]. The S2

cleavage exposes its internal fusion peptide which gets inserted to the target cell
membrane [63].
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Fig.13. Schematic depiction of sequential proteolytic cleavage of SARS CoV
spike[62]: Cleavage at the S1/S2 boundary facilitates cleavage at the S2 position
exposing the fusion peptide which can then be inserted into the target membrane for
membrane fusion to occur.(FP: Fusion peptide; HR1: Heptad repeat 1; TM:
Transmembrane domain)
MHV2, like SARS CoV, emerges from cells with uncleaved spikes. Engagement
of the virus with CEACAM on a target cell, triggers stepwise conformational changes in
spike[15, 24] which begin with the exposure of the viral fusion peptide .The insertion of
the fusion peptide into the cell membrane results in a pre-hairpin trimer with one end
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embedded in the cell membrane and the other in the viral envelope. Protease-mediated
cleavage results in a fusogenic fragment containing the fusion peptide, HR1 and HR2 and
the transmembrane domain, triggering the next step of conformation changes. Formation
of the 6-helix bundle (6HB), characterized by a proteinase K-resistant core appearing as a
~53kDa band in western blot images[15], draws the two membranes close together
resulting eventually in membrane fusion as depicted in Figure 2.
MHV2 viruses produced in TMPRSS2 expressing cells are less infectious (Fig12,
left panel) but the cleavage pattern of spikes on these viruses is different from that
observed in MHV A59 spikes. In producer cells that do not express TMPRSS2, MHV2
spike is synthesized and assembled in an uncleaved form on the emerging virion but
when producer cells express TMPRSS2, the spikes on the emerging viruses are cleaved
and appear as a ~55kDa band (Fig 12, right panel) which corresponds to the proteinase-K
resistant core of the 6-helix bundle (6HB) usually formed during fusion events after the
interaction of spike with its receptor. It is possible, that as in the case of SARS Spike, the
timing of MHV2 spike cleavage is crucial in virus infectivity. Spike cleavage in MHV2
during virus production probably occurs in the absence of receptor engagement and hence
could be an inactivating cleavage event. But, during MHV2 entry, when the virus is
bound to its cell-surface receptor, the ensuing conformation changes of spike could
expose previously hidden, potentially activating TMPRSS2-cleavage site(s). Cleavage at
the newly exposed site(s) of spike by TMPRSS2, expressed on the virus-target cell, could
therefore possibly be an entry-activating event.
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Unlike MHV2 and SARS-CoV, MHV A59 spikes are synthesized precleaved at
S1/S2 during biogenesis. This study reveals that the intracellular MHV A59 S cleavage is
not the only activating step required for successful infection (Fig 10A and B). Spike
requires further cleavage, perhaps at or near the S2

region, by either cell surface serine

or endosomal acidophilic proteases, since inhibition of these proteases resulted in a
decrease in viral entry of up to a 1000-fold . The extents of inhibition by either the serine
protease inhibitor aprotinin or the endosomal protease inhibitor bafilomycin further
suggests that on entering target cells, the viruses can undergo two different, independent
activation pathways. About two-thirds of the entering viruses can get activated at cell
surfaces by serine-proteases that are inhibited by aprotinin. The other one-third of the
entering viruses do not get activated in this way and are then activated in endosomes by
acidophilic proteases, likely cathepsins, that are inhibited by bafilomycin. Either of the
two activation processes are sufficient for virus entry – the aprotinin-sensitive activation
does not require additional bafilomycin-sensitive activation and vice versa. The action of
these proteases could result in cleavage at the S2

region, exposing the fusion peptide

for subsequent insertion into target cell membranes as depicted in Fig.14.
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Figure 14 .Model for MHV A59 entry effects of proteases on target cells: Figure
modified from “Role of Spike Protein Endodomains in Regulating Coronavirus Entry”
Shulla, A., et al., JBC, 2009[31] . Conformation change occurring upon receptor binding
by the S1 subunit of MHV spike exposes the S2 cleavage site to the action of target cells
proteases. Cleavage at the S2 site (middle panel) exposes the fusion peptide (FP) which
is inserted into the cell membrane forming the prehairpin trimer intermediate.
Viruses emerging from TMPRSS2 expressing cells were less stable (Fig 11), had
lower infectivities (Fig8B) and appeared to be relatively resistant to aprotinin (Fig. 10A).
It is possible that a portion of the viruses secreted from TMPRSS2 expressing cells bear
spikes that have been cleaved at the S2

cleavage site and have their fusion peptides

exposed and pre-primed for target cell membrane insertion. The 70kDa S2 fragments that
appear in viruses from TMPRSS2 positive cells (Fig 9) could correspond to the preprimed S2 fragments which do not need further activation by target cell proteases and
hence are insensitive to protease inhibition. On the other hand, while some viruses are
secreted with pre-primed spikes, it appears that another fraction of the progeny virions
have inactivating spike cleavage with S2 fragments ~50kDa in size which also
corresponds to the overall lowered infectivities of viruses emerging from TMPRSS2
expressing cells.
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Fig.15 depicts a model for the effects of TMPRSS2 protease activity on MHV
production. In an infected cell, progeny MHV virion morphogenesis occurs by budding at
the ERGIC. It is possible that during maturation and egress through the compartments of
the host cell secretory pathway, the viruses come in contact with newly synthesized
TMPRSS2 proteins being transported to the plasma membrane. The proximity of protease
and substrate within the same intracellular compartments likely facilitates TMPRSS2mediated cleavage of accessible spikes into the ~ 80kDa, 72kDa, 70kDa and 50kDa
fragments observed in the western blot image in Fig 9B. It is not clear, however, whether
the TMPRSS2-mediated cleavage affects the non-covalent interactions between S1 and
S2 and whether the cleaved spikes on the expelled viruses are maintained as stable S1-S2
complexes.
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Figure 15. Model for TMPRSS2 effects on MHV production: In an infected cell,
nascent MHV virions and newly synthesized TMPRSS2 proteins are transported together
to the cell surface by secretory vesicles of the exocytic pathway. Transport in the same
intracellular compartments renders spike proteins on the virions accessible to the
proteolytic activities of TMPRSS2 and viruses emerge from the cells bearing cleaved
spikes.
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It is conceivable that cleavage by TMPRSS2 in MHV- producer cells results in
the loss of segments of spike that are important for stable S1-S2 interaction. The
decreased thermo-stability observed in these viruses (Fig.11) could be a consequence of a
decreased stability in S1-S2 interactions causing spontaneous S1 detachment not unlike
that observed in MHV JHM.SD [8, 68, 69].
Proteases play a crucial role in coronavirus spike activation and the timing and
location of the cleavage can make the difference between an activating and an
inactivating cleavage. Unlike influenza and HMPV viruses, which are activated in
producer cells by TMPRSS2 mediated cleavage of their precursor glycoproteins during
transit through the cellular exocytic pathway, MHV coronaviruses emerging from
TMPRSS2-expressing cells are overall less infectious and are subject to inactivating
spike cleavage. The “pre-priming” of some MHV A59 viruses by TMPRSS2 in the
producer cells is balanced by the inactivating spike cleavage of some emerging viruses.
The findings from this study have implications for the study of host cell factors
that play a role in coronavirus infection and evolution. Collectively, the data indicate that
the coronavirus entry activation that is facilitated by TMPRSS2 [38] might be tempered
by the subsequent inactivation of progeny viruses by the proteases, possibly as a
mechanism of host cell resistance. Development of host cell resistance can necessitate coevolution of viruses to select for more virulent variants as a mechanism to establish
persistent infection [71-73]. It is conceivable that serial passaging of coronaviruses in
cells expressing TMPRSS2 could result in the emergence of mutations in the inactivating
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cleavage sites recognized by the protease thus producing more virulent TMPRSS2resistent viruses

APPENDIX
EFFECT OF ANTI VIRAL LECTIN GRIFFITHSIN ON CORONAVIRUS
INFECTION

[39]

[40]

Griffithsin (GFRT) is a mannose binding plant lectin with potent anti-viral
properties that was isolated from red algae Griffithsia in New Zealand in
2004, during an NCI, National Institutes of Health sponsored search for
natural product extracts exhibiting anti-HIV activity [75]. Lectins are
commonly occurring proteins in nature that bind carbohydrates and play
varied roles in cellular processes. The propensity of lectins to bind
carbohydrates makes them attractive candidates for antiviral agents since
enveloped viruses such as retroviruses and coronaviruses are embedded
with heavily glycosylated surface glycoproteins, which when targeted can
lead to disruption of the virus-host cell interactions and inhibit virus
entry[74].
GFRT binds to oligosaccharides on HIV gp120 and inhibits cytopathic
effects of HIV-1 at picomolar concentrations, without having cytotoxic
effects on cells at high concentrations, indicating its promise as a potential
anti-viral microbicide [75].
A recent study indicates that GFRT mediated inhibition extends to
coronaviruses and intranasal administration of the lectin prevents lethal
pulmonary infection in mice [76]. The goal of this study was a better
understanding of the mechanism of action of GFRT, which could aid in
the development of preventative and therapeutic measures such as topical
anti-viral microbicides.
Methods
Cells and viruses
The cell lines used in this study,293T cells and HeLa-CD4 cells stably
transfected to express CD4[77], were cultured in DMEM supplemented
with 10%FBS, 2mM L-Glutamine, 100 units/ml penicillin, 100µg/ml
streptomycin and 0.01M sodium HEPES (pH7.4). Murine 17cl1
fibroblasts used to passage MHV A59 viruses were grown in media
containing DMEM , 5% tryptose phosphate broth, 5% FCS and 0.01M
sodium HEPES (pH7.4). SFM used in pseudovirus transduction and cellcell fusion assays contained 2mM L-Glutamine, 100 units/ml penicillin,
100µg/ml streptomycin and 0.01M sodium HEPES (pH7.4).
Plasmid DNAs
plasmids used in the study included, pNL4-3LUC-R-E( encoding the
HIV-1 strain NL4 genome with firefly luciferase gene inserted into the
pNL4-3 nef gene and expressing luciferase as marker of gene
expression[49]), pcDNA 3.1 CEACAM (encoding CEACAM the receptor
for MHVs), pHEF-VSV G (encoding VSV glycoprotein G), pCAGGS
A59 S (encoding MHV A59 S) , pCAG T7pol (encoding T7 RNA
polymerase), pT7EMC-luc (encoding firefly luciferase under the control
of T7 RNA polymerase promoter.
Pseudovirus transductions
HIV-pseudotyped virions were produced by co-transfecting 293T cells,

[41]

via calcium phosphate, with pNL4-3LUC-R-E, and plasmid vectors
encoding MHV A59 S/VSV G/gp120/41 from HIV-1 JR-FL strain.
Pseudovirions secreted in the media were collected 48 hpi, clarified at
2000xg for 10min, 4οC and stored at -20 οC. For transductions, target
HeLa-CD4 cells were transfected, via lipofection[78] (using
LipofectamineTM 2000 transfection reagent, Invitrogen), with pcDNA
CEACAM. 24 hpt, the target cells were incubated with either SFM or
100nM, 200nM, 400nM Griffithsin (obtained from the NIH AIDS
Research and Reference Program) in SFM, for 20min at 22 οC. After
20min, the media was aspirated, pseudovirions were added and the plates
were spinoculated by centrifugation at 25 οC for 2 hours at 3000rpm.
After 2 days of transduction at 37 οC, the target cells were lysed and
luciferase activity measured.
Cell-cell fusion assay
Target 293T cells were co-transfected with pcDNA3.1 CEACAM and
pT7EMC-luc via calcium phosphate. Effector cells were produced by cotransfecting 293T cells with pCAGGS A59 S and pCAG-T7pol via
calcium phosphate. 28 hours post transfection, effector cells were
resuspended in serum free media (SFM) and overlaid on the target cells at
a 1:1 ratio and spinoculated at 500xg for 5min, at 4οC.100nM, 200nM,
400nM Griffithsin in SFM, or SFM alone, was added and the cells were
incubated at 37οC. After 4 hours, the cells were lysed and assayed for
luciferase accumulations.
Immunoprecipitation and immunoblotting
nCEACAM-Fc proteins[23] and protein G magnetic beads were
resuspended in HN buffer (25 mM Na Hepes, 150 mM NaCl )and
incubated at 22 οC for 1 hour. The beads were rinsed thrice with HNB
buffer (25 mM Na Hepes, 150 mM NaCl, 0.01% BSA) containing 0.5%
sodium deoxycholate, 0.5% NP40 to wash away unbound nCEACAM-Fc
proteins. The beads were then incubated with SFM (No GFRT), or
100nM, 200nM, 400nM GFRT in SFM at 22 οC for 20min.After rinsing
thrice with HNB buffer, the beads were incubated with MHV A59 viruses
at 37 οC for 1 hour. The beads were rinsed thrice in HNB and the proteins
were eluted from the beads by adding SDS-DTT solubilizer (.125 M Tris
{pH 6.8}, 10% dithiothreitol, 2% sodium dodecyl sulfate [SDS], 10%
sucrose, 0.004% bromophenol blue), and heating at 95 οC for 5min. The
samples were subjected to 12% SDS polyacrylamide gel electrophoresis
and the gels were transferred to polyvinylidine difluoride membranes
which were then blocked for 1 hour with 5% non-fat milk powder in
TBST (25 mM Tris-HCl {pH 7.5}, 140 mM NaCl, 2.7 mM KCl, 0.05%
Tween 20). Spike proteins were detected using monoclonal, anti-S2 (10G)
antibody (1:2000 in 2% milk in TBST), and GFRT was detected using
anti-GFRT antibody (1:1000 in 2% milk in TBST).

[42]

Results
Effect of GFRT on pseudovirus transductions
The effect of GFRT on coronavirus infections was examined using HIVpseudotyped MHV A59 S pseudoparticles in HeLa-CD4 cells transiently
expressing CEACAM receptor. Briefly, HIV-A59 S, HIV-VSV G and
HIV –JR-FL pseudoviruses were used to transduce HeLa-CD4 target
cells in the presence of increasing amounts of GFRT. 48 hours posttransduction, the target cells were lysed and assayed for luciferase
activities. HIV-JR-FL was used as a positive control, since the inhibitory
effect of GFRT on HIV has been documented [75]. The results (Fig 16)
revealed that the transduction ability of HIV-A59 S was decreased
almost 10-fold by Griffithsin, and this effect was specific to
coronaviruses since transduction potential of HIV-VSV G was not
affected.
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Figure16.Effect of GFRT on HIV-MHV A59 S pseudovirus transduction: HeLa-CD4
cells transfected to express CEACAM receptor were incubated with 100nM, 200nM,
400nM GFRT in serum free media for 20min at 22οC. Media was removed and the cells
were incubated with HIV-SARS S, HIV-VSV G and HIV-JR-FL for 2 days at 37 οC. 48
hours post-transduction, cells were lysed and luciferase activity was measured. Error bars
represent one standard deviation above and below the mean.
Effect of GFRT on virus: receptor interaction
To determine whether GFRT blocks virus-receptor interaction, a coimmunoprecipitation experiment was performed using an Fc-tagged,
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soluble form of CEACAM, the receptor for MHV A59, nCEACAM-Fc
[18, 23]. nCEACAM-Fc was captured on to protein G magnetic beads
and incubated with or without GFRT. MHV A59 viruses were then added
and after a one hour incubation period, proteins were subsequently eluted
from the beads and subjected to immunoblotting to detect Spike
proteins.The results revealed that GFRT bound CEACAM (Fig.17, lane
5), but did not inhibit the subsequent binding of the virion with the
receptor, even at higher concentrations (Fig 17, lanes 2, 3 and 4). The
data indicates that the site of action of GFRT is not at the stage of virusreceptor binding.

Figure 17: Effect of GFRT on virus-receptor binding: nCEACAM-Fc, the soluble
form of the receptor for MHV A59, bound to Protein A magnetic beads, was incubated
with the indicated concentrations of GFRT (Griffithsin) at 37ºC for 30min, washed,
followed by incubation with purified, wild type MHV A59 virus for 30 min at 37 ºC.The
samples were analyzed by SDS-PAGE and Western blotting with the indicated
antibodies. Lanes 6 and 7 are controls to ensure that GFRT and MHV A59 are not
binding the magnetic beads. Lanes 8 and 9 are GFRT and MHV A59 loading controls,
respectively.

[44]

3000000

RLU

2500000

2000000
1500000
1000000
No S

500000

0
No treatment

100nM
GFRT

200nM
GFRT

400nM
GFRT

Figure 18.Effect of GFRT on MHV A59 Spike-mediated cell-cell fusion: Target cells
(293T cells transfected with plasmids encoding CEACAM and Luciferase) were overlaid,
28hrs post-transfection, with Effector cells (293T cells transfected with plasmids
encoding MHV A59 Spike protein and T7 Polymerase) at 1:1 ratio and spinoculated at 4
º
C for 5min to facilitate Effector-Target cell contact without the initiation of fusion. The
indicated concentrations of Griffithsin (GFRT) were then added, and the Effector-Target
cells were co-incubated at 37 ºC for 4hrs, lysed and assayed for Luciferase activity. Error
bars represent one standard deviation above and below the mean.
Effect of GFRT on MHV A59 Spike mediated cell-cell fusion
Data from Fig 17 indicated that GFRT may be exerting its MHV A59
entry inhibiting effects at post-receptor-binding stages. To determine if
that was the case, MHV A59 S mediated cell-cell fusion assay was
performed in the presence of GFRT which was administered after ensuring
spike-CEACAM binding. Briefly, target cells were co-transfected with
plasmids encoding CEACAM and a luciferase reporter under the control
of T7 RNA polymerase promoter. Effector cells were co-transfected to
express MHV A59 S, and T7 RNA polymerase. At 28 hpt, the target cells
were overlaid with effector cells at a 1:1 ratio and spinoculated to facilitate
spike-CEACAM binding. The spinoculation was performed at 4 ºC, a
temperature that arrests receptor-mediated spike conformational changes
and membrane fusion [24]. GFRT was then added to the cells and the
reaction shifted to 37 ºC to allow for cell-cell fusion. Cells were lysed after
a 4 hour co-culture and assayed for luciferase accumulations. As shown in
Figure 18, GFRT inhibited MHV A59 Spike mediated cell-cell fusion in a
concentration dependent manner. In this experiment, the effector cells
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bearing the MHV Spike protein were overlaid on the CEACAM receptorbearing target cells and spinoculated at 4 ºC (to ensure spike-receptor
binding without fusion initiation), followed by the addition of increasing
concentrations of GFRT and shift to 37 ºC. The cell-cell fusion decreased
to ~60% of the “No treatment” control in the presence of 100nM GFRT
and up to 40% in the presence of 200nM and 400nM GFRT. The result
indicated that the cell-cell fusion blocking effect of GFRT takes place
after virus: cell receptor interaction. Collectively, figures 17 and 18
suggested that the inhibitory effect of GFRT on MHV A59 virus is not at
the receptor binding stage, but at the fusion event following the receptor
binding.
Conclusion
Lectins are carbohydrate binding agents (CBA) that are being investigated
for their anti-viral properties against enveloped viruses [74], and in recent
studies, have been shown to be effective against various coronaviruses
and other members of the order Nidovirales[79]. Lectins like GFRT can
act by binding with glycans on virus surface proteins and preventing the
virus-cell interactions required for viral entry[80].This study revealed that
though GFRT does not prevent interaction of MHV A59 spike with its
receptor CEACAM, it inhibits cell fusion by up to ~60% . Thus, the
inhibition of coronavirus entry by GFRT is at the level of post-receptor
binding events. MHV A59 spike is a heavily glycosylated protein with 18
potential N-glycosylation sites. Figure 19 is a schematic depiction of
MHV A59 spike with the putative N-glycosylation sites indicated.
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Figure 19. Schematic depiction of the putative N-linked glycosylation sites on MHV
A59 Spike.
It is possible that GFRT inhibits the fusion events which follow the
conformational changes of MHV Spike that are associated with receptor
binding[26]. By binding glycans near the fusion peptide, GFRT could
obstruct insertion of the fusion peptide into the target cell membrane. It is
also possible that GFRT binds to glycans in the vicinity of HR1 and HR2
peptides preventing the formation of the stable six-helix bundle (6HB)
which draws the viral and cellular membranes close together for fusion to
occur. Further studies of MHV testing the appearance of 6HB in the
presence of GFRT may reveal more insight into its site of action.
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